GEODE CAPITAL MANAGEMENT, LLC - RIGEL PHARMACEUTICALS INC ownership

RIGEL PHARMACEUTICALS INC's ticker is RIGL and the CUSIP is 766559603. A total of 151 filers reported holding RIGEL PHARMACEUTICALS INC in Q4 2020. The put-call ratio across all filers is 0.88 and the average weighting 0.1%.

Quarter-by-quarter ownership
GEODE CAPITAL MANAGEMENT, LLC ownership history of RIGEL PHARMACEUTICALS INC
ValueSharesWeighting
Q3 2023$3,831,358
-12.8%
3,547,100
+4.1%
0.00%
-100.0%
Q2 2023$4,395,094
+1.7%
3,407,050
+4.0%
0.00%0.0%
Q1 2023$4,322,460
+91400.0%
3,274,591
+4.0%
0.00%0.0%
Q4 2022$4,724
-99.9%
3,149,470
+2.0%
0.00%0.0%
Q3 2022$3,641,000
+5.0%
3,086,408
+0.6%
0.00%0.0%
Q2 2022$3,467,000
-62.1%
3,068,459
+0.3%
0.00%0.0%
Q1 2022$9,148,000
+10.9%
3,059,728
-1.7%
0.00%0.0%
Q4 2021$8,248,000
-26.8%
3,112,660
+0.2%
0.00%
-50.0%
Q3 2021$11,273,000
-12.8%
3,105,540
+4.2%
0.00%0.0%
Q2 2021$12,929,000
+35.4%
2,979,126
+6.7%
0.00%
+100.0%
Q1 2021$9,551,000
+4.9%
2,792,937
+7.4%
0.00%
-50.0%
Q4 2020$9,101,000
+48.5%
2,600,312
+1.8%
0.00%
+100.0%
Q3 2020$6,128,000
+34.0%
2,553,615
+2.2%
0.00%0.0%
Q2 2020$4,573,000
+20.5%
2,499,379
+2.7%
0.00%0.0%
Q1 2020$3,796,000
-60.7%
2,433,581
-46.1%
0.00%0.0%
Q4 2019$9,668,000
+121.3%
4,518,510
+93.4%
0.00%0.0%
Q3 2019$4,368,000
-27.6%
2,335,865
+1.0%
0.00%0.0%
Q2 2019$6,034,000
+15.6%
2,312,155
+13.9%
0.00%0.0%
Q1 2019$5,218,000
-41.2%
2,030,430
-47.4%
0.00%0.0%
Q4 2018$8,874,000
+67.6%
3,858,376
+133.9%
0.00%0.0%
Q3 2018$5,295,000
+13.5%
1,649,772
+0.1%
0.00%0.0%
Q2 2018$4,664,000
+3.3%
1,648,253
+29.3%
0.00%0.0%
Q1 2018$4,513,000
-6.9%
1,275,104
+2.1%
0.00%
-50.0%
Q4 2017$4,847,000
+81.2%
1,249,380
+18.6%
0.00%
+100.0%
Q3 2017$2,675,000
-5.0%
1,053,500
+2.1%
0.00%0.0%
Q2 2017$2,815,000
-16.0%
1,031,371
+1.9%
0.00%0.0%
Q1 2017$3,350,000
+84.9%
1,012,241
+32.9%
0.00%0.0%
Q4 2016$1,812,000
-38.5%
761,672
-5.1%
0.00%0.0%
Q3 2016$2,946,000
+76.7%
802,861
+7.3%
0.00%0.0%
Q2 2016$1,667,000
+9.7%
747,946
+2.3%
0.00%0.0%
Q1 2016$1,520,000
-23.5%
731,016
+11.5%
0.00%0.0%
Q4 2015$1,986,000
+39.3%
655,695
+13.5%
0.00%0.0%
Q3 2015$1,426,000
-19.0%
577,561
+5.3%
0.00%0.0%
Q2 2015$1,760,000
-8.6%
548,450
+1.6%
0.00%0.0%
Q1 2015$1,926,000
+84.8%
539,695
+17.5%
0.00%0.0%
Q4 2014$1,042,000
+21.9%
459,326
+4.2%
0.00%0.0%
Q3 2014$855,000
-46.1%
440,779
+0.8%
0.00%0.0%
Q2 2014$1,587,000
-5.6%
437,345
+0.8%
0.00%0.0%
Q1 2014$1,682,000
+40.8%
433,672
+3.4%
0.00%0.0%
Q4 2013$1,195,000
-19.5%
419,300
+1.1%
0.00%0.0%
Q3 2013$1,485,000
+25.1%
414,741
+16.7%
0.00%0.0%
Q2 2013$1,187,000355,3010.00%
Other shareholders
RIGEL PHARMACEUTICALS INC shareholders Q4 2020
NameSharesValueWeighting ↓
DAFNA Capital Management LLC 1,847,087$4,119,0003.26%
Sio Capital Management, LLC 1,333,696$2,974,0001.52%
Boxer Capital, LLC 700,000$1,561,0001.38%
Palo Alto Investors LP 5,386,534$12,012,0000.91%
ACUTA CAPITAL PARTNERS, LLC 747,748$1,667,0000.80%
SENZAR ASSET MANAGEMENT, LLC 1,443,003$3,217,897,0000.70%
Ghost Tree Capital, LLC 800,000$1,784,0000.52%
NEA Management Company, LLC 3,243,150$7,232,0000.38%
Rhenman & Partners Asset Management AB 850,000$1,896,0000.34%
Rock Springs Capital Management LP 1,750,000$3,903,0000.29%
View complete list of RIGEL PHARMACEUTICALS INC shareholders